Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 3 |
2022 | 4 |
2023 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study.
Eur J Neurol. 2023 Jan;30(1):224-234. doi: 10.1111/ene.15563. Epub 2022 Sep 26.
Eur J Neurol. 2023.
PMID: 36097739
Free PMC article.
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group.
Vernieri F, et al.
J Headache Pain. 2021 May 3;22(1):35. doi: 10.1186/s10194-021-01247-1.
J Headache Pain. 2021.
PMID: 33941080
Free PMC article.
Item in Clipboard
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.
Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Schiano Di Cola F, d'Onofrio F, Finocchi C, Bertuzzo D, Bono F, Ranieri A, Albanese M, Messina R, Doretti A, Di Piero V, Cevoli S, Barbanti P, Vernieri F; GARLIT Study Group.
Altamura C, et al.
J Neurol. 2022 Nov;269(11):5848-5857. doi: 10.1007/s00415-022-11226-4. Epub 2022 Jun 28.
J Neurol. 2022.
PMID: 35763113
Free PMC article.
Item in Clipboard
When should we consider chronic patients as non-responders to monoclonal antibodies targeting the CGRP pathway?
Altamura C, Cevoli S, Brunelli N, Aurilia C, Fofi L, Egeo G, Barbanti P, Vernieri F; GARLIT Study Group collaborators.
Altamura C, et al.
J Neurol. 2022 Feb;269(2):1032-1034. doi: 10.1007/s00415-021-10772-7. Epub 2021 Aug 28.
J Neurol. 2022.
PMID: 34455469
No abstract available.
Item in Clipboard
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group.
Vernieri F, et al.
Eur J Neurol. 2022 Apr;29(4):1198-1208. doi: 10.1111/ene.15197. Epub 2021 Dec 6.
Eur J Neurol. 2022.
PMID: 34826192
Item in Clipboard
Cite
Cite